Biogen/Elan hope updated Tysabri label will lend confidence to patients/prescribers
This article was originally published in Scrip
Executive Summary
The EC has approved the inclusion of anti-JC virus (JCV) antibody status to Biogen Idec/Elan's Tysabri (natalizumab) label "to aid in stratifying patients at risk for developing progressive multifocal leukoencephalopathy (PML)". Long-term growth potential of Tysabri could be dependent on patient risk stratification for PML, but it not yet clear what proportion of potential Tysabri patents would be tested for JCV status.